MRK
Merck & Company Inc
NYSE: MRK · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$110.95
+0.84% today
Updated 2026-04-29
Market cap
$276.38B
P/E ratio
15.37
P/S ratio
4.25x
EPS (TTM)
$7.28
Dividend yield
2.83%
52W range
$71 – $124
Volume
9.8M
WallStSmart proprietary scores
59
out of 100
Grade: C+
Hold
Investment rating
4.0
Growth
C4.8
Quality
C9.5
Profitability
A+4.0
Valuation
C3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$129.74
+16.94%
12-Month target
$116.11
+4.65%
Intrinsic (DCF)
$96.48
Margin of safety
-15.07%
4 Strong Buy14 Buy11 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 28.10% — above average
+ ROE 36.90% — strong efficiency
+ Free cash flow $1.82B — positive
Risks
- Piotroski 3/9 — weak financial health
- 15.07% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $59.28B | $60.12B | $64.17B | $65.01B | $65.01B | $67.4B |
| Net income | $14.52B | $365.00M | $17.12B | $18.25B | $2.96B | — |
| EPS | — | — | — | — | $7.28 | $5.09 |
| Free cash flow | $14.71B | $9.14B | $18.10B | $12.36B | $1.82B | — |
| Profit margin | 24.49% | 0.61% | 26.68% | 28.08% | 28.10% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | SEIDMAN, CHRISTINE E | Buy | 68 | $120.29 |
| 2026-03-31 | GLOCER, THOMAS H | Buy | 405 | $120.29 |
| 2026-03-31 | COE, MARY ELLEN | Buy | 249 | $120.29 |
Peer comparison
Smart narrative
Merck & Company Inc trades at $110.95. representing a P/E of 15.37x trailing earnings. Our Smart Value Score of 59/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. TTM revenue stands at $65.01B. with profit margins at 28.10%. Our DCF model estimates intrinsic value at $96.48.
Frequently asked questions
What is Merck & Company Inc's stock price?
Merck & Company Inc (MRK) trades at $110.95.
Is Merck & Company Inc overvalued?
Smart Value Score 59/100 (Grade C+, Hold). DCF value $96.48.
What is the price target of Merck & Company Inc (MRK)?
The analyst target price is $129.74, representing +16.9% upside from the current price of $110.95.
What is the intrinsic value of Merck & Company Inc (MRK)?
Based on our DCF model, intrinsic value is $96.48, a -15.1% margin of safety versus $110.95.
What is the future stock price of MRK by 2030?
Our research-backed model estimates Merck & Company Inc could reach $134.28 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Merck & Company Inc's revenue?
TTM revenue is $65.01B.
Piotroski F-Score?
3/9 — weak financial health.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio4.25x
ROE36.90%
Beta0.28
50D MA$118.60
200D MA$99.21
Shares out2.47B
Float2.47B
Short ratio—
Avg volume9.8M
Performance
1 week-4.00%
1 month-8.53%
3 months+1.56%
YTD+4.53%
1 year—
3 years—
5 years—